SCHEMBL257208

SCHEMBL257208

Cc1ccc(-c2c(C)nn3c(-c4ccc(F)cc4)cc(N4CCC[C@H]4CO)nc23)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 1/20 0.45
SCN9A Q15858 1/20 0.45
HPGD P15428 3/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
MAPK1 P28482 2/20 0.41
USP2 O75604 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KMT2A Q03164 1/20 0.40
MAPT P10636 5/20 0.39
TP53 P04637 2/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
EGLN2 Q96KS0 1/20 0.37
BCL6 P41182 1/20 0.37
ITGB2 P05107 1/20 0.37
ICAM1 P05362 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15020613 1.00 FPR2 (0.45) FPR2SCN9AHPGDALDH1A1KDM4E
SCHEMBL15020738 0.95 KMT2A (0.43) FPR2SCN9AHPGDMAPK1HSD17B10
SCHEMBL15042187 0.94 MAPT (0.47) FPR2SCN9AHPGDALDH1A1KDM4E
SCHEMBL15021317 0.93 MAPT (0.47) FPR2SCN9AHPGDALDH1A1KDM4E
SCHEMBL15021006 0.93 TP53 (0.46) FPR2SCN9AHPGDALDH1A1KDM4E
SCHEMBL15020736 0.92 FPR2 (0.43) FPR2SCN9AHPGDALDH1A1KDM4E
SCHEMBL15042156 0.92 MAPT (0.49) HPGDALDH1A1KDM4EMAPK1TSHR
SCHEMBL15020749 0.92 MAPT (0.49) HPGDALDH1A1KDM4EMAPK1TSHR
SCHEMBL15020689 0.91 FPR2 (0.42) FPR2SCN9AHPGDALDH1A1KDM4E
SCHEMBL15020615 0.91 FPR2 (0.42) FPR2SCN9AHPGDALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 FPR2 2908/4885SCN9A 615/4885HPGD 1531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.